Novel platform technologies enhance biomanufacturing efficiency and drug screening capabilities. The collaboration between MaxCyte and Ori Biotech streamlines autologous cell therapy production, integrating electroporation with advanced cell culture systems. Additionally, Genes2Me's OnePCR system gains FDA clearance, enabling rapid integrated qPCR diagnostics. At the molecular level, breakthroughs in metal halide perovskite processing yield highly durable solar cells, and engineered modular alkyl growth in amines advances synthetic organic chemistry. Together, these innovations accelerate translational research and therapeutic development pipelines.